Ascendis Pharma A/S (ASND) stock

ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30

$267.07+7.79 (+3.00%)

Close on Nov 12, 2026Market cap $16.55BP/E 21.7Yield –

Ascendis Pharma A/S EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Ascendis Pharma A/S's EV/EBITDA was 54.0× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	54.0×	–

Parsed from the XBRL in Ascendis Pharma A/S's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ASND.

Revenue growth113.4% · median 25.9%

Gross margin91.3% · median 96.3%

Operating margin25.4% · median -20.5%

Net margin70.8% · median -13.9%

Advertisement
300 × 250

See a number that looks wrong?